E-Newsletter - December 2020


Investigators from Alliance for Clinical Trials in Oncology and Alliance Foundation Trials, LLC working to advance research in the treatment and prevention of breast cancer presented a wide range of topics at the upcoming San Antonio Breast Cancer Symposium (SABCS) December 8-11. The virtually-held meeting, in its 43rd year, is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

Here's a snapshot of Alliance and AFT participation at this year's meeting.

Award Presentations
Alliance investigator Laura Esserman, MD, MBA, received the 2020 Brinker Award for Scientific Distinction in Clinical Research, which was established by Susan G. Komen in 1992 and recognizes advances in the understanding of underlying mechanisms in breast cancer and the clinical setting.

Dr. Esserman is the Alfred A. de Lorimier Endowed Chair in General Surgery, Professor of Surgery and Radiology and Director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco. She is being recognized for her seminal contributions in clinical research, including her innovative clinical trial programs, notably the I-SPY trials, which have become models to accelerate the development of safe, effective, personalized treatment, detection, and prevention options and improve the delivery of clinical care for breast cancer patients.
Plenary Lecture
Alliance investigator Elizabeth A. Mittendorf, MD, PhD, presented a plenary lecture "Local Regional Management Following Neoadjuvant Therapy: Minding the Knowledge Gaps."  
Dr. Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and Associate Chair for Research in the Department of Surgery at the Brigham and Women's Hospital. She is also the Director of the Breast lmmuno-Oncology Program and Co-Director of the Breast Cancer Clinical Research Program at the Dana-Farber/Brigham and Women's Cancer Center. Her presentation was sponsored by SABCS and the Society for Surgical Oncology.
Both Drs. Mittendorf and Esserman's lectures are available virtually on-demand from the SABCS website.
Special Session
Alliance investigator Charles Perou, MD, presented one of the opening special sessions "Setting the Stage for Health Equity, Collaboration and Partnership," alongside Maimah Karmo, the founder and CEO of the Tigerlily Foundation.  
Dr. Perou is the Distinguished Professor of Molecular Oncology at the UNC Lineberger Comprehensive Care Center. The session was sponsored by Tigerlily and the American Association for Cancer Research (AACR).

Alliance A011106
Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
Publication Number: GS4-05
Lead author: Cynthia X. Ma
Clinical Trials.gov Identifier: NCT01953588
Alliance A011106
Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
Publication Number: PD2-10

Lead author: Matthew J. Ellis
Clinical Trials.gov Identifier: NCT01953588
CALGB 40601
A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies
Publication Number: PS10-02
Lead author: Sung Gwe Ahn
CALGB 40603
Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival
Publication Number: PD9-03
Lead author: Jonathan H Shepherd
ClinicalTrials.gov Identifier: NCT00861705
IBCSG-24-02/BIG 2-02 (SOFT-TEXT)
The role of CYP2D6-mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)
Publication Number: PD2-09
Lead author: Matthew P. Goetz
IBCSG 48-14/BIG 8-13/A221405
Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)
Publication Number: PS12-17
Lead author: Ann H. Partridge
ClinicalTrials.gov Identifier: NCT02308085
N9831 (Alliance)
Prognostic value of clinical treatment score post-5 years (CTS5) and late relapse risk in hormone receptor-positive HER2-positive breast cancer in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) and NSABP B-31 (NRG) trials
Publication Number: PS6-03
Lead author: Tanyami Pai
Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer (AFT-05)
Publication Number: PD2-03
Lead author: Erica Mayer
ClinicalTrials.gov Identifier: NCT02513394
Comparing an operation to monitoring, with or without endocrine therapy (COMET): A prospective randomized trial for low-risk DCIS (AFT-25)
Publication Number: OT-08-02
Lead author: Thomas Lynch
ClinicalTrials.gov Identifier: NCT02926911



For other articles in this issue of the Alliance E-News newsletter, see below.